RecruitingNCT06549413
18F-FSPG PET/CT as a Non-Invasive Imaging Biomarker for Treatment Response to Chemoradiation in Esophageal Cancer
Sponsor
M.D. Anderson Cancer Center
Enrollment
60 participants
Start Date
Aug 23, 2023
Study Type
OBSERVATIONAL
Conditions
Summary
This study is being done to learn how 18F-FSPG PET/CT scan results may be related to the response to chemotherapy and radiation in patients with esophageal cancer.
Eligibility
Min Age: 18 Years
Inclusion Criteria5
- \* ≥ 18 years of age
- Patients with locally advanced esophageal cancer
- Patients with untreated documented carcinoma of the esophagus that is \> 2 cm who are going to receive systemic therapy concurrently with radiation as primary therapy
- Ability to provide written informed consent in accordance with institutional policies
- Female subjects of childbearing potential must have a negative serum or urine pregnancy test within 1 week of the proposed investigational PET/CT scan(s) prior to injection of the investigational radiopharmaceutical
Exclusion Criteria4
- \* Body weight ≥ 400 pounds or body habitus or disability that will not permit the imaging protocol to be performed
- Pregnant or lactating females
- Have an allergy to intravenous contrast
- eGFR \< 30
Interventions
OTHERNon-Interventional Study
Non-interventional study
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06549413
Related Trials
The Vanguard Study: Testing a New Way to Screen for Cancer
NCT0699589836 locations
National Cancer Institute "Cancer Moonshot Biobank"
NCT04314401152 locations
PET/CT Imaging to Evaluate Cardiac Radiation Damage in Patients With Lung or Esophageal Cancer, EUCLID Trial
NCT057759391 location
CCRT Followed by PD-1 Inhibitor Maintenance Therapy in Locally Advanced ESCC
NCT069645681 location
Impact of Prehabilitation in Oncology Via Exercise- Esophageal (IMPROVE-Esophageal)
NCT068725151 location